Servier Ventures is the corporate venture capital arm of Servier, the French pharmaceutical company. Launched in 2026 with €200 million in capital, the fund is focused on accelerating biotech innovation across Europe, particularly in oncology and neurology—two of Servier’s core R&D areas.
In January 2026, Servier announced the launch of Servier Ventures, backed with €200 million4 in capital commitments. This is the company's first direct startup-focused investment vehicle after years of collaborating with external VCs.
The fund’s strategy is to back biotech companies with breakthrough science and help accelerate their development through both capital and access to Servier’s internal expertise.
The goal is to position Servier as a preferred partner for biotech founders seeking not just funding, but strategic scientific input and long-term collaboration. Servier Ventures will operate independently while maintaining close ties to Servier’s internal R&D and business development teams.
Leadership
Servier Ventures is led by Alexis Vandier, who brings scientific and strategic experience from within Servier Group. Vandier will oversee investment strategy, portfolio development, and alignment with Servier’s broader innovation goals.
Investment Strategy
The fund looks to invest early in companies with validated platforms or differentiated therapeutic approaches in oncology and neurology. Servier Ventures provides capital alongside potential access to preclinical and clinical expertise, with an eye toward building long-term, strategic relationships rather than short-term returns.
Notable Investments
As a newly launched fund, Servier Ventures has not yet announced its initial portfolio companies. The firm is actively sourcing deals in the biotech ecosystem and is expected to announce early deals in 2026.
Notable Exits
No exits to date. This is Servier's first fund dedicated to direct startup investments.
Other
Founders benefit not only from the capital but from close integration with Servier’s scientific teams and infrastructure. Servier Ventures plans to co-invest with leading VCs and offer startups access to expertise that can help accelerate research and development toward regulatory and clinical milestones.
France
